{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:58:38Z","timestamp":1787947118433,"version":"build-2784847793"},"reference-count":53,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1124\/dmd.113.052100","type":"journal-article","created":{"date-parts":[[2013,8,3]],"date-time":"2013-08-03T04:41:17Z","timestamp":1375504877000},"page":"1843-1851","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib\u2014an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer"],"prefix":"10.1016","volume":"41","author":[{"given":"Venkateswaran C.","family":"Pillai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Venkataramanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Parise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Christner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gramignoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Strom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Rudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"Beumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.113.052100_bib1","first-page":"548","article-title":"A drug-drug interaction study to evaluate the effect of rifampicin on the pharmacokinetics of the EGF receptor tyrosine kinase inhibitor, erlotinib, in healthy subjects","volume":"22","author":"Abbas","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1124\/dmd.113.052100_bib2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00228-006-0127-x","article-title":"Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine","volume":"62","author":"Backman","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.113.052100_bib3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/clpt.2008.242","article-title":"Pharmacokinetic considerations for new targeted therapies","volume":"85","author":"Baker","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.052100_bib4","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/clpt.2012.243","article-title":"Without therapeutic drug monitoring, there is no personalized cancer care","volume":"93","author":"Beumer","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.052100_bib5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/135965350501000413","article-title":"Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs","volume":"10","author":"Boffito","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1124\/dmd.113.052100_bib6","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00520-012-1645-y","article-title":"Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review","volume":"21","author":"Borkar","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1124\/dmd.113.052100_bib7","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1208\/s12248-009-9103-6","article-title":"Prediction of hepatic clearance in human from in vitro data for successful drug development","volume":"11","author":"Chiba","year":"2009","journal-title":"AAPS J"},{"key":"10.1124\/dmd.113.052100_bib8","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/cid\/cis613","article-title":"The rising challenge of non-AIDS-defining cancers in HIV-infected patients","volume":"55","author":"Deeken","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1124\/dmd.113.052100_bib9","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/aps.2010.218","article-title":"Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib","volume":"32","author":"Dong","year":"2011","journal-title":"Acta Pharmacol Sin"},{"key":"10.1124\/dmd.113.052100_bib10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1365-2125.1997.00644.x","article-title":"Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir","volume":"44","author":"Eagling","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.113.052100_bib11","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1200\/JCO.2012.43.5362","article-title":"Evidence for therapeutic drug monitoring of targeted anticancer therapies","volume":"30","author":"Gao","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.113.052100_bib12","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3727\/096368911X600939","article-title":"Development and application of purified tissue dissociation enzyme mixtures for human hepatocyte isolation","volume":"21","author":"Gramignoli","year":"2012","journal-title":"Cell Transplant"},{"key":"10.1124\/dmd.113.052100_bib13","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.2008.19.3995","article-title":"Overcoming CYP1A1\/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.113.052100_bib14","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/clpt.2011.164","article-title":"Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy","volume":"90","author":"Katzenmaier","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.113.052100_bib15","first-page":"83","article-title":"Erlotinib in the treatment of advanced pancreatic cancer","volume":"2","author":"Kelley","year":"2008","journal-title":"Biologics"},{"key":"10.1124\/dmd.113.052100_bib16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1124\/dmd.108.023853","article-title":"Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes","volume":"37","author":"Kilford","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.052100_bib17","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00280-012-1831-0","article-title":"A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer","volume":"69","author":"Kobayashi","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.113.052100_bib18","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1124\/dmd.32.5.512","article-title":"Induction and inhibition of cytochromes P450 by the St. John\u2019s wort constituent hyperforin in human hepatocyte cultures","volume":"32","author":"Komoroski","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.052100_bib19","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1124\/dmd.108.025734","article-title":"Quantitative prediction of in vivo profiles of CYP3A4 induction in humans from in vitro results with a reporter gene assay","volume":"37","author":"Kozawa","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.052100_bib20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1023\/A:1007451911843","article-title":"Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: evaluation of model drugs terfenadine and rifampin","volume":"13","author":"Li","year":"1997","journal-title":"Cell Biol Toxicol"},{"key":"10.1124\/dmd.113.052100_bib21","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1158\/1078-0432.CCR-07-0088","article-title":"Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes","volume":"13","author":"Li","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.113.052100_bib22","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.pharmtox.41.1.535","article-title":"Interindividual variability in inhibition and induction of cytochrome P450 enzymes","volume":"41","author":"Lin","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.113.052100_bib23","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1124\/dmd.105.007765","article-title":"Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers","volume":"34","author":"Ling","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.052100_bib24","series-title":"Molecular Cell Biology","author":"Lodish","year":"2000"},{"key":"10.1124\/dmd.113.052100_bib25","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1124\/dmd.106.010793","article-title":"Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes","volume":"34","author":"Lu","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.052100_bib26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1124\/dmd.106.011346","article-title":"A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data","volume":"35","author":"Lu","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.052100_bib27","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/JTO.0b013e3181d3ccf2","article-title":"Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancer","volume":"5","author":"Makinson","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1124\/dmd.113.052100_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/157016212799937227","article-title":"Human immunodeficiency virus-associated malignancies: a therapeutic update","volume":"10","author":"Malfitano","year":"2012","journal-title":"Curr HIV Res"},{"key":"10.1124\/dmd.113.052100_bib29","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1158\/1078-0432.CCR-04-0746","article-title":"Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities","volume":"10","author":"Messersmith","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.113.052100_bib30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3816\/CCC.2010.n.043","article-title":"Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer","volume":"9","author":"Messersmith","year":"2010","journal-title":"Clin Colorectal Cancer"},{"key":"10.1124\/dmd.113.052100_bib31","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1200\/JCO.2007.11.6210","article-title":"Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101","volume":"25","author":"Miller","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.113.052100_bib32","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1535-7163.MCT-10-0731","article-title":"Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins","volume":"10","author":"Minematsu","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/dmd.113.052100_bib33","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00280-011-1792-8","article-title":"A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors","volume":"69","author":"Padda","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.113.052100_bib34","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJM200103293441307","article-title":"Interactions among drugs for HIV and opportunistic infections","volume":"344","author":"Piscitelli","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.113.052100_bib35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00228-007-0396-z","article-title":"The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition","volume":"64","author":"Rakhit","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.113.052100_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00280-009-1133-3","article-title":"A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin","volume":"66","author":"Ranson","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.113.052100_bib37","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3816\/CLC.2009.n.004","article-title":"Toxicity of targeted therapy in non-small-cell lung cancer management","volume":"10","author":"Ricciardi","year":"2009","journal-title":"Clin Lung Cancer"},{"key":"10.1124\/dmd.113.052100_bib38","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1124\/dmd.105.004259","article-title":"A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes","volume":"33","author":"Riley","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.113.052100_bib39","doi-asserted-by":"crossref","unstructured":"Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, Yates JW, Ku MS, Gibson CR, and He H et al (2011). PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance. J Pharm Sci DOI:10.1002\/jps.22552 [published ahead of print]","DOI":"10.1002\/jps.22552"},{"key":"10.1124\/dmd.113.052100_bib40","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S1470-2045(11)70056-0","article-title":"Use of antineoplastic agents in patients with cancer who have HIV\/AIDS","volume":"12","author":"Rudek","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1124\/dmd.113.052100_bib41","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1200\/JCO.2007.13.1128","article-title":"Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity","volume":"26","author":"Rudin","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.113.052100_bib42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1006\/bbrc.2000.2902","article-title":"Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes","volume":"273","author":"Runge","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.113.052100_bib43","first-page":"1696","article-title":"Erlotinib\/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas","volume":"21","author":"Senderowicz","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"10.1124\/dmd.113.052100_bib44","doi-asserted-by":"crossref","first-page":"18422","DOI":"10.1073\/pnas.1010693107","article-title":"Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir","volume":"107","author":"Sevrioukova","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.113.052100_bib45","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jnci\/djr076","article-title":"Cancer burden in the HIV-infected population in the United States","volume":"103","author":"Shiels","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1124\/dmd.113.052100_bib46","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2165\/00003088-200140120-00002","article-title":"Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors","volume":"40","author":"Smith","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.113.052100_bib47","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors","volume":"35","author":"van Erp","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1124\/dmd.113.052100_bib48","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0022-3565(24)34868-2","article-title":"Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat","volume":"290","author":"Witherow","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.113.052100_bib49","doi-asserted-by":"crossref","unstructured":"Xu C, Desta Z (2013). In vitro Analysis and Quantitative Prediction of Efavirenz Inhibition of Eight Cytochrome P450 (CYP) Enzymes: Major Effects on CYPs 2B6, 2C8, 2C9 and 2C19. Drug Metab Pharmacokinet PMID: 23385314 [published ahead of print]","DOI":"10.2133\/dmpk.DMPK-12-RG-124"},{"key":"10.1124\/dmd.113.052100_bib50","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-007-0494-8","article-title":"Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors","volume":"61","author":"Yamamoto","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.113.052100_bib51","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/00498250500159371","article-title":"Prediction of oral clearance from in vitro metabolic data using recombinant CYPs: comparison among well-stirred, parallel-tube, distributed and dispersion models","volume":"35","author":"Yamamoto","year":"2005","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.113.052100_bib52","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s12032-012-0349-y","article-title":"Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis","volume":"30","author":"Yoshida","year":"2013","journal-title":"Med Oncol"},{"key":"10.1124\/dmd.113.052100_bib53","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-200544030-00005","article-title":"Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs","volume":"44","author":"Zhou","year":"2005","journal-title":"Clin Pharmacokinet"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624098787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624098787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.113.052100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T19:13:54Z","timestamp":1739906034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624098787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0090955624098787"],"URL":"https:\/\/doi.org\/10.1124\/dmd.113.052100","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ritonavir and Efavirenz Significantly Alter the Metabolism of Erlotinib\u2014an Observation in Primary Cultures of Human Hepatocytes That Is Relevant to HIV Patients with Cancer","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.113.052100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}